Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 73 entries
View as:

The Mass Balance and Biotransformation of [14C]Donafenib in Healthy Adult Man

Phase: N/A Priority: Normal
NCT ID: NCT04816123 Org: User:
Start: 10/09/18 End: 12/18/18 Due: 12/18/19

Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06938880 Org: User:
Start: 05/31/25 End: 04/30/28 Due: 04/30/29

A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT05526222 Org: User:
Start: 07/14/22 End: 09/30/25 Due: 09/30/26

Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.

Phase: N/A Priority: Normal
NCT ID: NCT04851535 Org: User:
Start: 07/28/21 End: 11/01/22 Due: 11/01/23

A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata

Phase: N/A Priority: Normal
NCT ID: NCT04445363 Org: User:
Start: 08/12/20 End: 12/01/24 Due: 12/01/25

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

Phase: N/A Priority: Normal
NCT ID: NCT05255237 Org: User:
Start: 03/25/22 End: 06/28/24 Due: 06/28/25

A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06246695 Org: User:
Start: 10/27/21 End: 01/12/22 Due: 01/12/23

Study of ZGGS18 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05584800 Org: User:
Start: 11/15/22 End: 11/01/25 Due: 11/01/26

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT04217993 Org: User:
Start: 01/07/20 End: 08/03/22 Due: 08/03/23

Study of ZGGS15 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05864573 Org: User:
Start: 07/19/23 End: 08/31/26 Due: 08/31/27

A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Phase: N/A Priority: Normal
NCT ID: NCT04971551 Org: User:
Start: 12/31/24 End: 07/31/25 Due: 07/31/26

A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

Phase: N/A Priority: Normal
NCT ID: NCT05688839 Org: User:
Start: 04/30/24 End: 03/31/25 Due: 03/31/26

Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal

Phase: N/A Priority: Normal
NCT ID: NCT04971473 Org: User:
Start: 09/10/21 End: 07/05/23 Due: 07/05/24

Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04503902 Org: User:
Start: 10/15/20 End: 12/31/23 Due: 12/31/24

A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03602495 Org: User:
Start: 08/29/18 End: 07/15/21 Due: 07/15/22

Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)

Phase: N/A Priority: Normal
NCT ID: NCT05702788 Org: User:
Start: 09/30/22 End: 04/23/24 Due: 04/23/25

Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02645981 Org: User:
Start: 03/31/16 End: 12/17/19 Due: 12/17/20

Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients

Phase: N/A Priority: Normal
NCT ID: NCT04137185 Org: User:
Start: 06/10/19 End: 12/29/20 Due: 12/29/21

Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02229071 Org: User:
Start: 04/30/14 End: 10/30/16 Due: 10/30/17

Donafenib for Previously Treated Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02870582 Org: User:
Start: 12/28/16 End: 04/30/20 Due: 04/30/21

Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

Phase: N/A Priority: Normal
NCT ID: NCT04402723 Org: User:
Start: 11/06/18 End: 02/09/22 Due: 02/09/23

ADME Study of [14C]-Jaktinib in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05150717 Org: User:
Start: 01/04/22 End: 01/30/22 Due: 01/30/23

A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.

Phase: N/A Priority: Normal
NCT ID: NCT06237400 Org: User:
Start: 05/26/22 End: 05/31/25 Due: 05/31/26

Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT07024277 Org: User:
Start: 08/31/25 End: 12/31/27 Due: 12/31/28

Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata

Phase: N/A Priority: Normal
NCT ID: NCT04034134 Org: User:
Start: 11/18/19 End: 11/26/21 Due: 11/26/22